INBSHIGH SIGNALFINANCIAL10-K

INBS experienced severe financial deterioration with cash collapsing 84% to just $1.0M and stockholders' equity declining 64% to $3.0M, creating immediate liquidity concerns.

The dramatic cash burn and equity erosion indicate the company is facing a potential going concern situation and may need immediate capital raising or risk insolvency. The doubling of outstanding shares from 4.2M to 9.0M suggests significant dilutive equity financing occurred during this period, likely at distressed valuations.

Comparing 2025-08-15 vs 2024-09-18View on EDGAR →
FINANCIAL ANALYSIS

INBS shows severe financial distress with cash plummeting 84% to only $1.0M while total assets declined 40% and stockholders' equity fell 64%. Despite revenue-generating activities continuing (accounts receivable increased 38%), gross profit declined 12% indicating operational challenges. The overall picture signals a company in financial crisis that has likely undergone significant dilutive financing to survive, with minimal cash reserves remaining for operations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-83.8%
$6.3M→$1.0M

Cash declined 83.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-64%
$8.3M→$3.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-51.5%
$8.5M→$4.1M

Current assets declined 51.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-40.1%
$13.8M→$8.2M

Total assets contracted 40.1% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+38.4%
$430K→$595K

Receivables surged 38.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Inventory
Balance Sheet
-18.3%
$778K→$635K

Inventory reduced 18.3% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
-12.5%
$1.4M→$1.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2025-08-15
PRIOR — 2024-09-18
ADDED
As of August 12, 2025, there were 8,979,152 of the registrant s Common Stock issued and outstanding.
On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ( IFP ), a company registered in England and Wales.
Our Testing Platforms Intelligent Fingerprinting Platform: The Company s current active product is the Intelligent Fingerprinting Platform, which consists of the proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
Biosensor Platform : Under the terms of an Amended and Restated License Agreement dated September 12, 2019 (the BPT License Agreement ), between the Company and Life Science Biosensor Diagnostics Pty Ltd ( LSBD or Licensor ), the Company held an exclusive license in the Asia Pacific Region ( APAC Region ) to the Licensor s proprietary rights to the biosensor technology (the Biosensor IP ) used in the biosensor platform we refer to as the Biosensor Platform Technology ( BPT ), or simply the Biosensor Platform .
This platform consists of a small, printable modified organic thin-film transistor strip designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte.
We refer to products that use the BPT as the Licensed Products .
This platform technology has the potential to develop a range of Point of Care Tests.
We understand that following the appointment of a liquidator to LSBD on July 21, 2023, the Biosensor IP we licensed from LSBD has reverted back to the University of Newcastle.
Following our ongoing discussions with the University, it is the Company s understanding that the University of Newcastle cannot finalize licensing of the Biosensor IP until the liquidation of LSBD is complete.
As the timeline for the completion of LSBD s liquidation is unknown, the Company does not expect any updates or finalization of any license terms until this occurs.
REMOVED
As of September 16, 2024, there were 4,249,782 of the registrant s Common Stock issued and outstanding.
On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ( IFP ), a company registered in England and Wales (the IFP Acquisition ).
The Company s current product portfolio includes: Intelligent Fingerprinting Platform: A proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
The Biosensor Platform A biosensor platform we refer to as the Biosensor Platform Technology ( BPT ), or simply the Biosensor Platform, consists of a small, printable modified organic thin-film transistor strip that we license across the Asia Pacific Region ( APAC Region ) from Life Science Biosensor Diagnostics Pty Ltd ( LSBD or Licensor ).
The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte.
This platform technology has the potential to develop a range of Point of Care Tests ( POCT ), including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
We understand that following the appointment of a liquidator to LSBD, the intellectual property rights licensed by us from the Licensor (LSBD) have reverted to the University of Newcastle.
The Company is in early-stage discussions regarding the potential restructuring of future licensing of BPT and products with the University of Newcastle.
A timeline for these discussions has not yet been established.
3 Highlights of Achievements and Developments Our major highlights of achievements for the fiscal year 2024: As of June 30, 2024, the Company had a cash balance of approximately $6.30 million after raising approximately $14.56 million throughout the fiscal year (after deducting fees, discounts, closing costs, and other expenses payable by the Company), through an underwritten public offering, a warrant inducement transaction, and a private placement of the Company s securities.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →